CLONICEL (Clonidine HCl sustained release)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Attention Deficit Hyperactivity Disorder

Conditions

Attention Deficit Hyperactivity Disorder

Trial Timeline

Jan 1, 2008 → Jun 1, 2010

NCT ID

NCT00723190

About CLONICEL (Clonidine HCl sustained release)

CLONICEL (Clonidine HCl sustained release) is a phase 3 stage product being developed by Shionogi for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00723190. Target conditions include Attention Deficit Hyperactivity Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Attention Deficit Hyperactivity Disorder were approved

Approved (11) Terminated (1) Active (9)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

🔄AtomoxetineEli LillyPhase 3

✅AtomoxetineEli LillyApproved

✅Atomoxetine hydrochloride + PlaceboEli LillyApproved

🔄Donepezil hydrochloride + PlaceboEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00723190	Phase 3	Completed	Jan 1, 2008	Jun 1, 2010	Attention Deficit Hyperactivity Disorder

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine + Placebo	Eli Lilly	Phase 2/3	38
Atomoxetine	Eli Lilly	Approved	35
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Phase 3	40
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine hydrochloride + Placebo	Eli Lilly	Approved	43
Donepezil hydrochloride + Placebo	Eisai	Phase 3	40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)	Eli Lilly	Phase 2/3	38
Atomoxetine + Placebo	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Pre-clinical	26
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Placebo	Eli Lilly	Approved	43
atomoxetine	Eli Lilly	Phase 3	40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine Hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo	Eli Lilly	Phase 3	40